Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016
Published Jun 08, 2016
178 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016, provides an overview of the Retinitis Pigmentosa (Retinitis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)
- The report reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Retinitis Pigmentosa (Retinitis) therapeutics and enlists all their major and minor projects
- The report assesses Retinitis Pigmentosa (Retinitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline

  
Source:
Document ID
GMDHC8168IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents29
  List of Tables91
  List of Figures101
Introduction111
  Global Markets Direct Report Coverage111
Retinitis Pigmentosa (Retinitis) Overview121
Therapeutics Development132
  Pipeline Products for Retinitis Pigmentosa (Retinitis) Overview131
  Pipeline Products for Retinitis Pigmentosa (Retinitis) Comparative Analysis141
Retinitis Pigmentosa (Retinitis) Therapeutics under Development by Companies152
Retinitis Pigmentosa (Retinitis) Therapeutics under Investigation by Universities/Institutes171
Retinitis Pigmentosa (Retinitis) Pipeline Products Glance183
  Late Stage Products181
  Clinical Stage Products191
  Early Stage Products201
Retinitis Pigmentosa (Retinitis) Products under Development by Companies213
Retinitis Pigmentosa (Retinitis) Products under Investigation by Universities/Institutes241
Retinitis Pigmentosa (Retinitis) Companies Involved in Therapeutics Development2530
  Acucela Inc.251
  Amarantus Bioscience Holdings, Inc.261
  Amgen Inc.271
  Applied Genetic Technologies Corporation281
  Asklepios BioPharmaceutical, Inc.291
  Astellas Pharma Inc.301
  Caladrius Biosciences, Inc.311
  Dompe Farmaceutici S.p.A.321
  Genable Technologies Limited331
  Genethon341
  GenSight Biologics S.A.351
  Grupo Ferrer Internacional, S.A.361
  ID Pharma Co., Ltd.371
  InFlectis BioScience381
  International Stem Cell Corporation391
  Ionis Pharmaceuticals, Inc.401
  M's Science Corporation411
  Mimetogen Pharmaceuticals Inc.421
  Nanovector s.r.l.431
  Orphagen Pharmaceuticals, Inc.441
  QLT Inc.451
  RegenxBio Inc.461
  ReNeuron Group Plc471
  SanBio, Inc.481
  Sanofi491
  Shire Plc501
  Spark Therapeutics, Inc.511
  Staidson (Beijing) Biopharmaceuticals Co., Ltd.521
  Sucampo Pharmaceuticals, Inc.531
  Sun Pharma Advanced Research Company Ltd.541
Retinitis Pigmentosa (Retinitis) Therapeutics Assessment559
  Assessment by Monotherapy Products551
  Assessment by Target562
  Assessment by Mechanism of Action582
  Assessment by Route of Administration602
  Assessment by Molecule Type622
Drug Profiles6474
  alvespimycin hydrochloride - Drug Profile641
    Product Description641
    Mechanism of Action641
    R&D Progress641
  AMRS-001 - Drug Profile651
    Product Description651
    Mechanism of Action651
    R&D Progress653
  Antibodies to Antagonize IL-6 for Retinitis - Drug Profile681
    Product Description681
    Mechanism of Action681
    R&D Progress681
  BNP-RP - Drug Profile691
    Product Description691
    Mechanism of Action691
    R&D Progress691
  CB-11 - Drug Profile701
    Product Description701
    Mechanism of Action701
    R&D Progress701
  Cell Therapy to Activate RPGR for Retinitis Pigmentosa - Drug Profile711
    Product Description711
    Mechanism of Action711
    R&D Progress711
  cutamesine - Drug Profile721
    Product Description721
    Mechanism of Action721
    R&D Progress722
  ECL-1 - Drug Profile741
    Product Description741
    Mechanism of Action741
    R&D Progress741
  emixustat hydrochloride - Drug Profile751
    Product Description751
    Mechanism of Action751
    R&D Progress752
  FAB-111 - Drug Profile771
    Product Description771
    Mechanism of Action771
    R&D Progress771
  Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile781
    Product Description781
    Mechanism of Action781
    R&D Progress781
  Gene Therapy for Ocular Diseases - Drug Profile791
    Product Description791
    Mechanism of Action791
    R&D Progress791
  Gene Therapy for Retinitis Pigmentosa - Drug Profile801
    Product Description801
    Mechanism of Action801
    R&D Progress801
  Gene Therapy for Retinitis Pigmentosa - Drug Profile811
    Product Description811
    Mechanism of Action811
    R&D Progress811
  Gene Therapy for Retinitis Pigmentosa - Drug Profile821
    Product Description821
    Mechanism of Action821
    R&D Progress821
  Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile831
    Product Description831
    Mechanism of Action831
    R&D Progress831
  Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile841
    Product Description841
    Mechanism of Action841
    R&D Progress841
  Gene Therapy to Activate mVChR1 for Retinits Pigmentosa - Drug Profile851
    Product Description851
    Mechanism of Action851
    R&D Progress851
  Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile861
    Product Description861
    Mechanism of Action861
    R&D Progress861
  Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis - Drug Profile871
    Product Description871
    Mechanism of Action871
    R&D Progress871
  Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile881
    Product Description881
    Mechanism of Action881
    R&D Progress881
  Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile891
    Product Description891
    Mechanism of Action891
    R&D Progress891
  GS-030 - Drug Profile901
    Product Description901
    Mechanism of Action901
    R&D Progress902
  GT-038 - Drug Profile921
    Product Description921
    Mechanism of Action921
    R&D Progress922
  HORAPDE-6B - Drug Profile941
    Product Description941
    Mechanism of Action941
    R&D Progress941
  IFB-088 - Drug Profile951
    Product Description951
    Mechanism of Action951
    R&D Progress951
  ISIS-RHO2.5Rx - Drug Profile961
    Product Description961
    Mechanism of Action961
    R&D Progress961
  KIRA-6 - Drug Profile971
    Product Description971
    Mechanism of Action971
    R&D Progress971
  LPDF-003 - Drug Profile981
    Product Description981
    Mechanism of Action981
    R&D Progress981
  myriocin - Drug Profile991
    Product Description991
    Mechanism of Action991
    R&D Progress991
  N-acetyl cysteine amide - Drug Profile1001
    Product Description1001
    Mechanism of Action1001
    R&D Progress1001
  NT-501 - Drug Profile1011
    Product Description1011
    Mechanism of Action1011
    R&D Progress1013
  OCU-100 - Drug Profile1041
    Product Description1041
    Mechanism of Action1041
    R&D Progress1041
  Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile1051
    Product Description1051
    Mechanism of Action1051
    R&D Progress1052
  ReN-003 - Drug Profile1071
    Product Description1071
    Mechanism of Action1071
    R&D Progress1072
  RGX-321 - Drug Profile1091
    Product Description1091
    Mechanism of Action1091
    R&D Progress1092
  RST-001 - Drug Profile1111
    Product Description1111
    Mechanism of Action1111
    R&D Progress1111
  SAR-421869 - Drug Profile1121
    Product Description1121
    Mechanism of Action1121
    R&D Progress1122
  SB-623 - Drug Profile1141
    Product Description1141
    Mechanism of Action1141
    R&D Progress1142
  SHP-630 - Drug Profile1161
    Product Description1161
    Mechanism of Action1161
    R&D Progress1161
  Small Molecule for Retinitis Pigmentosa - Drug Profile1171
    Product Description1171
    Mechanism of Action1171
    R&D Progress1171
  Small Molecule for Retinitis Pigmentosa - Drug Profile1181
    Product Description1181
    Mechanism of Action1181
    R&D Progress1181
  Small Molecules for CNS Disorders and Ophthalmology - Drug Profile1191
    Product Description1191
    Mechanism of Action1191
    R&D Progress1191
  Small Molecules for Retinitis Pigmentosa - Drug Profile1201
    Product Description1201
    Mechanism of Action1201
    R&D Progress1201
  Small Molecules for Retinitis Pigmentosa - Drug Profile1211
    Product Description1211
    Mechanism of Action1211
    R&D Progress1211
  Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile1221
    Product Description1221
    Mechanism of Action1221
    R&D Progress1221
  STC-1 - Drug Profile1231
    Product Description1231
    Mechanism of Action1231
    R&D Progress1231
  Stem Cell Therapy for Age Related Macular Degeneration and Retinitis Pigmentosa - Drug Profile1241
    Product Description1241
    Mechanism of Action1241
    R&D Progress1242
  Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile1261
    Product Description1261
    Mechanism of Action1261

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Retinitis-Pigmentosa-Retinitis-Pipeline-Review-H1-2016-2088-15911>
  
APA:
Global Markets Direct - Market Research. (2016). Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Retinitis-Pigmentosa-Retinitis-Pipeline-Review-H1-2016-2088-15911>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.